search
Barnsley
Batley
Bedale
Beverley
Bingley
Bradford
Bridlington
Brighouse
Castleford
Catterick Garrison
Cleckheaton
Cottingham
Darlington
Dewsbury
Doncaster
Driffield
Elland
Filey
Goole
Guisborough
Halifax
Harrogate
Hawes
Hebden Bridge
Heckmondwike
Hessle
Holmfirth
Huddersfield
Hull
Ilkley
Keighley
Knaresborough
Knottingley
Leeds
Leyburn
Liversedge
Malton
Mexborough
Middlesborough
Mirfield
Morley
Normanton
Northallerton
Ossett
Otley
Pickering
Pontetfract
Pudsey
Redcar
Richmond
Ripon
Rotherham
Saltburn-by-the-Sea
Scarborough
Selby
Settle
Sheffield
Shipley
Skipton
Sowerby Bridge
Stockton-on-Tees
Tadcaster
Thirsk
Todmorden
Wakefield
Wetherby
Whitby
Yarm
York
Irbesartan Blood Pressure And Heart Medication Recalled From Pharmacies By MHRA
Today the Medicines and Healthcare products Regulatory Agency (MHRA) are recalling certain irbesartan containing products made by Actavis (now Accord) as a precautionary measure, due to possible N‑nitrosodiethylamine (NDEA) contamination.

There is no evidence at present that the impurity has caused any harm to patients and not all irbesartan products are affected. People should not stop their medication and should speak to a doctor or pharmacist if they have any concerns.

The recall follows a Europe-wide investigation into contamination of sartan products. MHRA twice recalled batches of valsartan to pharmacy level in 2018; valsartan containing medicines from Dexcel and Actavis (now Accord) were recalled in July and batches of valsartan containing medicines made by Mylan and Teva, were also recalled to pharmacy level in November.

The first recall occurred after an impurity, N-nitrosodimethylamine (NDMA), was identified as part of the manufacturing process in a valsartan active substance manufactured at one facility based in China. A second impurity, NDEA, was later discovered.

MHRA are working closely with other EU member states, the European Medicines Agency (EMA) and the European Directorate for the Quality of Medicines (EDQM) to ensure a thorough investigation and we will consider the impact in the UK and what actions may be necessary.

Dr Sam Atkinson MHRA’s Director of the Inspection, Enforcement and Standards Division said:

"Our highest priority is making sure the medicines you take are safe.

"Our investigation into potential contamination of sartan containing medicines, including irbesartan, is ongoing.

"At present, there is no evidence that medicines containing NDMA or NDEA have caused any harm to patients.

"Because of the risk associated with suddenly stopping high blood pressure medication, people are advised not to stop any treatments without consulting their doctor or pharmacist."

Irbesartan Blood Pressure And Heart Medication Recalled From Pharmacies By MHRA, 3rd January 2019, 9:32 AM